News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Jordi Remon: We had efficacy data on ADCs after osimertinib and PD in EGFR-mutant NSCLC
Jordi Remon/X
Mar 26, 2025, 17:42

Jordi Remon: We had efficacy data on ADCs after osimertinib and PD in EGFR-mutant NSCLC

Jordi Remon, Cancer Specialist at CIOCC Barcelona, shared on X:

“We had efficacy data ADCs after osi-PD in EGFRm NSCLC. Today good mPFS (9.5-11.7) with Osi+DatopotamAb Dxd after osi-PD. Data looks promising than chemo+Amiv. Better protection maintaining osi? Biomarker for dato? Toxicity is imp. Future trial: osi-DATOD vs Ami-CT?”

cancer CIOCC Jordi Remon OncoDaily Oncology
Special Coverage
Blog
Mar 31, 2025, 06:10
The lung cancer patient advocacy sessions at the ELCC 2025 were standout events - Lung Cancer Europe
Insight
Mar 31, 2025, 06:04
Yan Leyfman: Expanding Antibody Therapeutics with TCR Mimicry 
Blog
Mar 31, 2025, 05:50
Jennifer Bires: Proud to speak on AI and mental health at NCCS Cancer Advocacy’s Spring 2025 Cancer Policy Roundtable
Insight
Mar 31, 2025, 05:03
Jarushka Naidoo: My ELCC 2025 Top 3 - MARIPOSA, KRYSTAL7 and Deescalation trials
Blog
Mar 31, 2025, 04:59
Michael Sapienza: Federal funding for cancer and other disease research has been cut by more than $1 billion
Blog
Mar 31, 2025, 04:45
Amil Družić: Excited to be part of the upcoming Young Cancer Professionals Roundtable
Blog
Mar 31, 2025, 03:27
Inside Cancer Careers Podcast Concluding – Thank You to our guests and listeners for two incredible years: Train at NCI
Blog
Mar 31, 2025, 02:59
Ariana Znaor: Consultation period for International Classification of Diseases for Oncology, 4th Edition is extended
Blog
Mar 31, 2025, 02:16
Peter Pisters: Delighted to serve as keynote speaker at Opportunity Austin's quarterly meeting
Blog
Mar 30, 2025, 23:21
Sachin H. Jain: How has "expert bias" mislead you in your work?
Blog
Mar 30, 2025, 22:48
HESI THRIVE 2025 Seed Grant Program - Funding Opportunity for Innovative Cancer Research
Insight
Mar 30, 2025, 21:29
Bishoy Morris Faltas: AI model that predicts response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer